Core Insights - Inhibikase Therapeutics has appointed Chris Cabell, M.D. as President and Head of Research & Development, and John Adams, Ph.D. as Chief Scientific Officer, both with extensive experience in pulmonary arterial hypertension (PAH) [1][2] - The company aims to accelerate the development of IkT-001, an oral prodrug of imatinib mesylate, for the treatment of PAH, with plans to execute a Phase 2 clinical trial [2][6] - Vince Aurentz has joined the Board of Directors, bringing significant experience in corporate strategy and business development from his previous roles in the biopharmaceutical sector [2][5] Leadership Appointments - Chris Cabell, M.D. has a background as Chief Medical Officer at Arena Pharmaceuticals and Chief Executive Officer at CorHepta Pharmaceuticals, with a focus on cardiology and PAH [3] - John Adams, Ph.D. co-founded CorHepta and previously held senior positions at Iambic Therapeutics and Reneo Pharmaceuticals, specializing in research and translational science [4] - Vince Aurentz has held key leadership roles, including Executive Vice President at Arena Pharmaceuticals, contributing to corporate strategy and business development [5] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary diseases [6] - The company's lead product, IkT-001, targets PAH and is positioned as a potential innovative therapeutic option for patients suffering from this condition [6]
Inhibikase Announces Expansion of Senior Leadership Team